Table 4.
n | % | |
---|---|---|
Source patient is known | 108 | 32.7 |
Serologic testing of the source patient | ||
Hbs Ag positivity | 19 | 17.6 |
Anti HCV positivity | 20 | 18.5 |
Anti HIV positivity | 4 | 3.7 |
Negative | 65 | 60.2 |
Schedules for follow-up of exposed HCW | ||
RF | 119 | 36.1 |
V+RF | 35 | 10.6 |
V+IP+RF | 8 | 2.4 |
Antiretroviral prophylaxis+RF | 3 | 0.9 |
RF: regularly follow-up V: vaccination IP: immune prophylaxis.